Jamie Dlugosch

Jamie Dlugosch

InvestorPlace Writer

Jamie Dlugosch has over 20 years of experience in financial markets including investment banking, equity analysis and research and money management.

Previously, he was the publisher of Al Frank’s Prudent Speculator and CEO of Al Frank Investment Management Inc. He is the founder and editor of The Rational Investor.

Jamie earned his Master’s in Business Administration from the University of North Carolina. He currently lives in Minneapolis with his wife, Sarah, and their two daughters, Julia and Ellie.

Recent Articles

What Does Your Intuition Tell You?

By Jamie Dlugosch, InvestorPlace Writer

Investing in the stock market is really not as complex as many make it out to be. Cut through much of the noise and what you have left is a few basic fundamental principles and intuition.

Top 5 Corporate Bonds for 2009

By Jamie Dlugosch, InvestorPlace Writer

The corporate bond market suffered through one of the worst years in memory in 2008 as the credit markets worldwide collapsed. But from the detritus of the credit and equity markets of the past year, both investment-grade and high-yield corporate debt instruments appear in a strong position to experience a run-up in 2009. Within this sector, I have identified 5 corporate credits as my favorites for the year.

Digital River Prospers in Rough e-Commerce Rapids

By Jamie Dlugosch, InvestorPlace Writer

While the threats for continued growth for DRIV are substantial, the company has been adept at reacting to competitive forces. Management has guided the company to continued increases in market share and profitability.

Monsanto (MON) Outperforms. Agriculture a Safe Haven?

By Jamie Dlugosch, InvestorPlace Writer

Agricultural stocks should be considered a safe haven during economic weakness. Yet agricultural stocks were absolutely pummeled in the latter part of 2008. That being the case, an investment opportunity exists in this sector.

Keep an Eye on Gilead Sciences (GILD)

By Jamie Dlugosch, InvestorPlace Writer

We all know that the major pharmaceutical companies are struggling. Normally, in times of economic distress, shares of the big pharmaceutical companies are seen as a safe haven because of their consistent earnings and dividend payments.

Load More